pcDNA3 myc CIITA (P#808) Citations (11)
Originally described in: Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection.Kanazawa S, Okamoto T, Peterlin BM Immunity. 2000 Jan . 12(1):61-70. PubMed Journal
Articles Citing pcDNA3 myc CIITA (P#808)
| Articles |
|---|
| Semaphorin 3A alters endothelial cell immunogenicity by regulating Class II transactivator activity circuits. Schlahsa L, Zhang H, Battermann A, Verboom M, Immenschuh S, Eiz-Vesper B, Stripecke R, Engelmann K, Blasczyk R, Figueiredo C. Transfusion. 2014 Aug;54(8):1961-70. doi: 10.1111/trf.12631. Epub 2014 Mar 28. PubMed |
| Tumor-specific CD4+ T cells eradicate myeloma cells genetically deficient in MHC class II display. Tveita A, Fauskanger M, Bogen B, Haabeth OA. Oncotarget. 2016 Oct 11;7(41):67175-67182. doi: 10.18632/oncotarget.11946. PubMed |
| Swine Leukocyte Antigen Class II Is a Xenoantigen. Ladowski JM, Reyes LM, Martens GR, Butler JR, Wang ZY, Eckhoff DE, Tector M, Tector AJ. Transplantation. 2018 Feb;102(2):249-254. doi: 10.1097/TP.0000000000001924. PubMed |
| HLA Class II-Triggered Signaling Cascades Cause Endothelial Cell Proliferation and Migration: Relevance to Antibody-Mediated Transplant Rejection. Jin YP, Valenzuela NM, Zhang X, Rozengurt E, Reed EF. J Immunol. 2018 Apr 1;200(7):2372-2390. doi: 10.4049/jimmunol.1701259. Epub 2018 Feb 23. PubMed |
| Causal ALS genes impact the MHC class II antigen presentation pathway. Chi B, Ozturk MM, Paraggio CL, Leonard CE, Sanita ME, Dastpak M, O'Connell JD, Coady JA, Zhang J, Gygi SP, Lopez-Gonzalez R, Yin S, Reed R. Proc Natl Acad Sci U S A. 2023 Sep 26;120(39):e2305756120. doi: 10.1073/pnas.2305756120. Epub 2023 Sep 18. PubMed |
| The HLA-II immunopeptidome of SARS-CoV-2. Weingarten-Gabbay S, Chen DY, Sarkizova S, Taylor HB, Gentili M, Hernandez GM, Pearlman LR, Bauer MR, Rice CM, Clauser KR, Hacohen N, Carr SA, Abelin JG, Saeed M, Sabeti PC. Cell Rep. 2024 Jan 23;43(1):113596. doi: 10.1016/j.celrep.2023.113596. Epub 2023 Dec 20. PubMed |
| SARS-CoV-2 NSP5 antagonizes MHC II expression by subverting histone deacetylase 2. Taefehshokr N, Lac A, Vrieze AM, Dickson BH, Guo PN, Jung C, Blythe EN, Fink C, Aktar A, Dikeakos JD, Dekaban GA, Heit B. J Cell Sci. 2024 May 15;137(10):jcs262172. doi: 10.1242/jcs.262172. Epub 2024 May 22. PubMed |
| Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction. Dezhbord M, Kim SH, Park S, Lee DR, Kim N, Won J, Lee AR, Kim DS, Kim KH. Clin Mol Hepatol. 2024 Jul;30(3):539-560. doi: 10.3350/cmh.2024.0060. Epub 2024 May 14. PubMed |
| Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers. Cheong TC, Jang A, Wang Q, Leonardi GC, Ricciuti B, Alessi JV, Di Federico A, Awad MM, Lehtinen MK, Harris MH, Chiarle R. Nat Commun. 2024 Jun 14;15(1):5110. doi: 10.1038/s41467-024-49499-0. PubMed |
| Antibody ligation of HLA class II induces YAP nuclear localization and formation of cytoplasmic YAP condensates in human endothelial cells. Lone M, Anwar T, Sinnett-Smith J, Jin YP, Reed EF, Rozengurt E. Immunohorizons. 2025 Jan 27;9(3):vlae008. doi: 10.1093/immhor/vlae008. PubMed |
| MAP1LC3C repression reduces CIITA- and HLA class II expression in non-small cell lung cancer. Barbeau LMO, Beelen NA, Savelkouls KG, Keulers TGH, Wieten L, Rouschop KMA. PLoS One. 2025 Feb 10;20(2):e0316716. doi: 10.1371/journal.pone.0316716. eCollection 2025. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.